ID   NCI-H3255DR
AC   CVCL_DI56
SY   H3255DR
DR   Wikidata; Q54908037
RX   PubMed=20118985;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804).
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DI55 ! NCI-H3255GR
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 5
//
RX   PubMed=20118985; DOI=10.1038/onc.2009.526;
RA   Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M.,
RA   Rogers A., Lifshits E., Brown A., Lee C., Christensen J.G.,
RA   Kwiatkowski D.J., Engelman J.A., Janne P.A.;
RT   "Amplification of EGFR T790M causes resistance to an irreversible EGFR
RT   inhibitor.";
RL   Oncogene 29:2346-2356(2010).
//